Mojgan Zarif

Toronto, ON M5G2C4, Canada

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

Genomic Profile and Clinical Outcomes in Acute Myeloid Leukemia with Monosomal Karyotype.

Genomic Profile and Clinical Outcomes in Acute Myeloid Leukemia with Monosomal Karyotype.

Journal: International journal of molecular sciences

Published: May 05, 2025

Molecular genetic characterization of mixed-phenotype acute leukemia (MPAL) with BCR::ABL1 fusion.

Molecular genetic characterization of mixed-phenotype acute leukemia (MPAL) with BCR::ABL1 fusion.

Journal: Leukemia research

Published: December 27, 2024

Impact of secondary-type mutations in acute myeloid leukemia with CEBPA mutation.

Impact of secondary-type mutations in acute myeloid leukemia with CEBPA mutation.

Journal: EJHaem

Published: October 31, 2024

Oral pimonidazole unveils clinicopathologic and epigenetic features of hypoxic tumour aggressiveness in localized prostate cancer.

Oral pimonidazole unveils clinicopathologic and epigenetic features of hypoxic tumour aggressiveness in localized prostate cancer.

Journal: BMC cancer

Published: November 09, 2023

T/myeloid MPAL with biallelic CEBPA mutations.

T/myeloid MPAL with biallelic CEBPA mutations.

Journal: Blood

Published: October 26, 2023

A real-world analysis of clinical outcomes in AML with myelodysplasia-related changes: a comparison of ICC and WHO-HAEM5 criteria.

A real-world analysis of clinical outcomes in AML with myelodysplasia-related changes: a comparison of ICC and WHO-HAEM5 criteria.

Journal: Blood advances

Published: October 06, 2023

AML with CEBPA mutations: A comparison of ICC and WHO-HAEM5 criteria in patients with 20% or more blasts.

AML with CEBPA mutations: A comparison of ICC and WHO-HAEM5 criteria in patients with 20% or more blasts.

Journal: Leukemia research

Published: July 13, 2023

TP53 Mutations in AML Patients Are Associated with Dismal Clinical Outcome Irrespective of Frontline Induction Regimen and Allogeneic Hematopoietic Cell Transplantation.

TP53 Mutations in AML Patients Are Associated with Dismal Clinical Outcome Irrespective of Frontline Induction Regimen and Allogeneic Hematopoietic Cell Transplantation.

Journal: Cancers

Published: May 02, 2023

Impact of secondary-type mutations in NPM1 mutated AML.

Impact of secondary-type mutations in NPM1 mutated AML.

Journal: European journal of haematology

Published: January 23, 2023

Molecular characterization of AML-MRC reveals TP53 mutation as an adverse prognostic factor irrespective of MRC-defining criteria, TP53 allelic state, or TP53 variant allele frequency.

Molecular characterization of AML-MRC reveals TP53 mutation as an adverse prognostic factor irrespective of MRC-defining criteria, TP53 allelic state, or TP53 variant allele frequency.

Journal: Cancer medicine

Published: July 27, 2022

NPM1-mutated AML-MRC diagnosed on the basis of history of MDS or MDS/MPN frequently harbours secondary-type mutations and confers inferior outcome compared to AML with mutated NPM1.

NPM1-mutated AML-MRC diagnosed on the basis of history of MDS or MDS/MPN frequently harbours secondary-type mutations and confers inferior outcome compared to AML with mutated NPM1.

Journal: Leukemia research

Published: April 26, 2022

Showing 1-11 of 11

Last Updated: 09/26/2026